Nonalcoholic steatohepatitis (NASH) is an increasingly common cause of chronic liver disease worldwide. Currently, no specific pharmacologic therapy has been shown to treat NASH effectively. Because ...

The second study, by Dr Yaping Xu (Takeda Pharmaceuticals) and colleagues, was a retrospective analysis of the US healthcare plan database i3 Innovus. Xu et al report that risk of stroke and MI were ...

Pioglitazone is a thiazolidinedione antidiabetic, prescribed for type 2 diabetes in certain patients. It is used along with diet and exercise. It may be used alone or with other antidiabetic medicines ...

Amsterdam, The Netherlands, Sept. 19, 2007 -- New research, including two studies presented this week at the 43rd Annual Meeting of the European Association for the Study of Diabetes (EASD), further ...

No pharmacologic therapy has conclusively proved to be effective for the treatment of nonalcoholic steatohepatitis, which is characterized by insulin resistance, steatosis, and necroinflammation with ...

New research, including two studies presented this week at the 43rd Annual Meeting of the European Association for the Study of Diabetes (EASD), further support the cardiovascular safety of ACTOS(R) ...

Reason for posting: Pioglitazone is an oral hypoglycemic agent widely used as monotherapy or combination therapy for type 2 diabetes mellitus. However, a recent analysis by the drug's manufacturer of ...

Women with polycystic ovary syndrome (PCOS) tend to be overweight and insulin-resistant, but pioglitazone treatment improves their insulin sensitivity, and leads to improved ovulatory function. High ...

Orlando FL, June 5, 2004 – Type 2 diabetes and hypertension are commonly associated conditions, both of which carry an increased risk of cardiovascular disease. Results of a large, open-label, ...

New research, including two studies presented this week at the 43rd Annual Meeting of the European Association for the Study of Diabetes (EASD), further support the cardiovascular safety of ACTOS(R) ...